There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on ObsEva SA (NASDAQ:OBSV) and Audentes Therapeutics (NASDAQ:BOLD) with bullish sentiments.
ObsEva SA (OBSV)
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on ObsEva SA today and set a price target of $44. The company’s shares closed yesterday at $18.07.
Selvaraju commented:
“Valuation methodology, risks and uncertainties. Our risk-adjusted net present value (rNPV) approach ascribes $1.68B to linzagolix (formerly to nolasiban. We utilize an 85% probability of approval for linzagolix and 75% for nolasiban.”
According to TipRanks.com, Selvaraju is a 4-star analyst with an average return of 5.7% and a 44.5% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, EyePoint Pharmaceuticals Inc, and Bausch Health Companies Inc.
Currently, the analyst consensus on ObsEva SA is a Strong Buy with an average price target of $33.25.
See today’s analyst top recommended stocks >>
Audentes Therapeutics (BOLD)
H.C. Wainwright analyst Debjit Chattopadhyay maintained a Buy rating on Audentes Therapeutics today and set a price target of $40. The company’s shares closed yesterday at $37.65.
Chattopadhyay observed:
“Our Buy rating and $40 price target on shares of Audentes is based on sum-of-the-parts analysis of the company’s pipeline. We value the XLMTM commercial opportunity at $21/share, and CN at $19/share, each of which are based on a 5x P/ S multiple on peak sales of roughly $579M (XLMTM peak sales of about $300M and CN peak sales of approximately $279M in FY2025), discounted at 10% over an 8-year period. Our 5x P/S multiple is below the lower end of historic M&A within the sector (typically in the range of 7-9x).”
According to TipRanks.com, Chattopadhyay is a 3-star analyst with an average return of 2.7% and a 46.6% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Voyager Therapeutics Inc, and Mersana Therapeutics Inc.
Currently, the analyst consensus on Audentes Therapeutics is a Moderate Buy with an average price target of $40.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
